Ruth Ladenstein Advances in Neuroblastoma Research Congress 2016

Abstracts this author is presenting:

• Prognostic Factors in stage 4 neuroblastoma patients treated with Busulphan-Melphalan. Report from the European High Risk Neuroblastoma HR-NBL1/SIOPEN Trial. — Poster Session 2 with wine & cheese
• Final results of the randomised short term infusion (STI) of ch14.18/CHOmAB immunotherapy in combination with Aldesleukin: a report on outcome and toxicities from the HR-NBL1/SIOPEN trial — Plenary Session 4
• Ruth Ladenstein, Chair, SIOPEN-HR1; St. Anna Kinderkrebsforschung e.V. & Children's Cancer Research Institute Vienna, Austria  — Workshop 2 - Novel clinical trial design for advanced neuroblastoma: a debate